Business
BioSpectrum Asia
Bio-Thera Solutions & Tabuk Pharma to commercialise Stelara biosimilar in Saudi Arabia
China-based Bio-Thera Solutions Inc.,
1 min |
BioSpectrum Asia Feb 2025
BioSpectrum Asia
Merck strikes partnership worth $1.9 B with Chinese biotech Hansoh
Merck, known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.
1 min |
BioSpectrum Asia Feb 2025
BioSpectrum Asia
US FDA issues draft guidance for developers of AI-enabled medical devices
The US Food and Drug Administration (FDA) has issued draft guidance that includes recommendations to support development and marketing of safe and effective artificial intelligence (AI)enabled devices throughout the device's Total Product Life Cycle.
1 min |
BioSpectrum Asia Feb 2025
BioSpectrum Asia
PAHO launches interactive dashboard to monitor avian influenza in the Americas
The Pan American Health Organization (PAHO) has launched an interactive dashboard to monitor avian influenza A(H5N1) cases in the Americas.
1 min |
BioSpectrum Asia Feb 2025
BioSpectrum Asia
"China and Asia are already the global leaders of Antibody-drug conjugates"
Chime Biologics, based in Asia, has positioned itself as a global leader in the Contract Development and Manufacturing Organisation (CDMO) sector.
4 min |
BioSpectrum Asia Feb 2025
BioSpectrum Asia
Innovent Biologics enters into billion-dollar oncology deal with Roche
China-based Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, has announced a collaboration and exclusive license agreement with Swiss pharma firm Roche to advance the development of IBI3009, a novel DLL3-targeted antibody drug conjugate (ADC) candidate.
1 min |
BioSpectrum Asia Feb 2025
BioSpectrum Asia
"There remains a high unmet need for new & alternative treatment options for prurigo nodularis & atopic dermatitis"
Asia-Pacific region houses some of Galderma's fastest growing markets, where sales have fueled a strong performance.
5 min |
BioSpectrum Asia Feb 2025
BioSpectrum Asia
AbbVie Biopharma strengthens digital strategies for clinical trials in Taiwan
National Taiwan University Hospital (NTUH) and AbbVie Biopharmaceuticals GmbH Taiwan Branch (AbbVie) have signed a cooperation agreement, with the agreement jointly signed by President Ming-Shiang Wu of NTUH and General Manager Richard Sun of AbbVie.
1 min |
BioSpectrum Asia Feb 2025
BioSpectrum Asia
Lonza expands capsule manufacturing capacity in India and China
Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, has announced capacity expansions at its sites in Rewari (India) and Suzhou (China).
1 min |
BioSpectrum Asia Feb 2025
BioSpectrum Asia
Primo Biotech partners with SHINE Technologies to advance precision cancer care in APAC
Taiwan-based startup Primo Biotechnology has announced a strategic partnership with US-based SHINE Technologies, LLC, a global leader in nuclear medicine production.
1 min |
BioSpectrum Asia Feb 2025
BioSpectrum Asia
Singapore launches Global Heat Health Information Network Southeast Asia Hub
The Heat Resilience & Performance Centre (HRPC) at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) has been officially designated as the Global Heat Health Information Network (GHHIN) Southeast Asia (SEA) Hub, a recognition that underscores its leading role in advancing heat resilience.
1 min |
BioSpectrum Asia Feb 2025
BioSpectrum Asia
China approves GSK's Nucala for treatment of adults with chronic rhinosinusitis
China National Medical Products Administration (NMPA) has approved GSK's Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSWNP) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
1 min |
BioSpectrum Asia Feb 2025
BioSpectrum Asia
"We are dedicated to helping people of all ages see brilliantly"
The global leader in eye care for over 75 years, Alcon Inc. strives to help eye care professionals strengthen their practices and serve patients better, improving visual health worldwide. Through its innovative eye care portfolios, Alcon has established operations in 56 countries and serves patients in 140 countries. Jason Hoffe, Vice President, APAC Vision Care, Alcon, responsible for driving the vision care business in the region shares opportunities exist for the company and new developments in eye healthcare that are cause for optimism for patients in the region.
5 min |
BioSpectrum Asia Jan 2025
BioSpectrum Asia
Singapore Turns Tech Beacon with Revolutionary Pharma Manufacturing & Digital Transformation
In the current pharmaceutical manufacturing environment, linking information technology (IT) with operational technology (OT) systems is increasingly vital. This integration enables a seamless exchange of information between these two historically separate domains - one focused on data management and the other on overseeing physical operations. This enables various aspects of the manufacturing process to gain insights from one another to boost efficiency and refine strategic decision-making. Digital transformation is essential for directing companies through the complexities of implementation and ensuring a seamless shift to a data-driven, digitally optimized manufacturing landscape.
6 min |
BioSpectrum Asia Jan 2025
BioSpectrum Asia
Building the Future of Medicine
PRODUCT OF THE YEAR 2024 - Needle Free Injection System technology by IntegriMedical
4 min |
BioSpectrum Asia Jan 2025
BioSpectrum Asia
Emerging Leader in Cell & Gene Therapy
STARTUP OF THE YEAR 2024 - ImmunoACT
3 min |
BioSpectrum Asia Jan 2025
BioSpectrum Asia
Improving Access for Respiratory Healthcare
STARTUP OF THE YEAR 2024 - Aevice Health
4 min |
BioSpectrum Asia Jan 2025
BioSpectrum Asia
Making an Impact with a 'CliKX'
Dr Lynne Lim, Co-Founder & Chief Executive Officer, NousQ
4 min |
BioSpectrum Asia Jan 2025
BioSpectrum Asia
Eyeing 20-20 Vision of Excellence
Dr Jogin Desai, Co-Founder & Chief Executive Officer, Eyestem Research
4 min |
BioSpectrum Asia Jan 2025
BioSpectrum Asia
Refining the Use of Radiation
Dr Christian Behrenbruch, Managing Director and Group Chief Executive Officer (CEO), Telix Pharmaceuticals
3 min |
BioSpectrum Asia Jan 2025
BioSpectrum Asia
Honouring Innovators in Asia's Thriving Life Sciences Sector
Asia has, indeed, become the new hub for growth and innovation, with no signs of losing steam. To recognise the Asian companies and individuals for their commendable performance and achievements during 2023 and 2024, BioSpectrum Asia Excellence Awards 2024 ceremony was held at Hotel Fort Canning in Singapore on December 6, 2024.
2 min |
BioSpectrum Asia Jan 2025
BioSpectrum Asia
How To Control Indian Diabetes Growth
World Diabetes Day, observed on November 14, reminds us of the growing impact of diabetes on global health and the urgent need for collective action to prevent, diagnose, and manage this chronic condition. In 2024, the theme 'Breaking Barriers, Bridging Gaps' underscores the critical importance of accessible, high-quality diabetes care, especially for underrepresented communities. The Government of India has taken many measures intending to reduce the prevalence of diabetes and alleviate its long-term complications, contributing to a healthier future for all citizens.
4 min |
December 2024
BioSpectrum Asia
HIV Prevention Remains Elusive
On December 1, the world gathers every year to commemorate World AIDS Day, which serves as an important reminder that we must remain steadfast in our commitment to prevent new HIV (Human Immunodeficiency Virus) infections and provide essential services to all people living with HIV globally. In 2024, the 37th World AIDS Day opens with the theme, \"Collective Action: Sustain and Accelerate HIV Progress.\"
2 min |
December 2024
BioSpectrum Asia
Karnataka launches India's first GCC policy
Bengaluru Tech Summit 2024
8 min |
December 2024
BioSpectrum Asia
Innovations in Urological Imaging: Transforming Patient Care in India
Despite advancements in urological imaging, challenges persist in India, particularly regarding cost and accessibility. Government initiatives and public-private partnerships should expand access to imaging facilities. Continued research investment is crucial for developing cost-effective solutions.
5 min |
December 2024
BioSpectrum Asia
How strategic angel investment is driving global expansion in medtech and diagnostics
India has firmly established itself as a key player in the global medtech and diagnostics sectors. With a burgeoning healthcare ecosystem and a growing focus on innovation, the country offers a fertile ground for startups looking to scale their solutions both domestically and internationally. Central to this growth is the role of strategic angel investment, which not only provides financial backing but also offers critical mentorship and strategic direction to help these companies expand their reach.
4 min |
December 2024
BioSpectrum Asia
What's dampening the GLOBAL AMR BATTLE?
Although there have been significant national and worldwide efforts to provide financial incentives for antibiotic research and development, it is still unclear how best to fortify the existing programmes to further spur antibiotic innovation. The incentive programmes in place now are a crucial first step in enhancing the economic viability of antibiotic development. However, it seems like there isn't enough global coordination among all the programmes, which could lead to duplication of effort, funding gaps in the value chain, and the failure to include crucial AMR objectives. Let's dig deeper.
9 min |
December 2024
BioSpectrum Asia
Indian Lifesciences Industry Going Ahead in its Innovation Journey While Navigating Challenges
While India is a hub for biosimilar manufacturing and continues to build its capabilities to manufacture these complex therapeutics, Indian biopharma companies are building R&D capabilities and establishing public-private collaborations and Centre of Excellences (CoEs) to develop innovative biologics and advanced therapeutic modalities like cell and gene therapy (CGT) and mRNA vaccines and therapies, biopharma sector remained robust in 2023, accounting for $53.8 billion (35 per cent of the BioEconomy). The growth was primarily driven by advances in biotechnology, personalised medicine innovations, and an expanding market for biosimilars in 2024.
5 min |
December 2024
BioSpectrum Asia
BioPharma's Transformative & Strategic OUTLOOK 2025
The Indian biopharma industry witnessed notable transformative developments and announcements, marked by innovation, regulatory advancements, and market expansion this year. From achieving global recognition in biosimilars to advancing biomanufacturing capabilities and precision therapeutics, the sector has solidified its role as a key player in the global pharmaceutical landscape. This progress underscores India's strategic focus on leveraging its robust infrastructure, skilled talent pool, and government support to meet the evolving demands of the healthcare industry.
10+ min |
December 2024
BioSpectrum Asia
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
1 min |